{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:ambrisentan",
  "owner": "cardio",
  "kind": "drug",
  "slug": "ambrisentan",
  "name": "Ambrisentan",
  "aliases": [
    "LETAIRIS"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Ambrisentan, sold as Letairis, is an endothelin receptor antagonist. The US label lists treating pulmonary arterial hypertension (WHO Group 1) in adult patients, to improve exercise ability and delay clinical worsening; it also lists a second use, together with tadalafil, that this page does not describe. The label carries a boxed warning for embryo-fetal toxicity: it says the medicine is contraindicated during pregnancy because it may cause major birth defects. That risk concerns the unborn child and is recorded separately.",
  "summary_technical": "RxNorm ingredient 358274; UNII HW6NV07QEC. MeSH has no descriptor for ambrisentan (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Endothelin Receptor Antagonist, so the record is filed under the class page. The label read is the Gilead Sciences, Inc. label for Letairis, application NDA022081 (approved 2007-06-15 as a new molecular entity in Drugs@FDA), effective 2026-06-22 in openFDA. The label's second indication, in combination with tadalafil, is not recorded. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the boxed-warning title and one sentence, the mechanism sentence and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "358274",
      "normalized_value": "358274",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "HW6NV07QEC",
      "normalized_value": "HW6NV07QEC",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels",
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label describes ambrisentan as an antagonist of the endothelin receptor subtype ET A, with high selectivity for ET A over ET B."
  },
  "content_digest": "a0fd9281afd23fa33eeee526d43f98df57e87d98616b628409c7cdea5062ab84",
  "review": {
    "content_digest": "a0fd9281afd23fa33eeee526d43f98df57e87d98616b628409c7cdea5062ab84",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-letairis-label-fetal-warning",
      "owner": "cardio",
      "subject_entity_id": "cardio:ambrisentan",
      "category": "safety",
      "statement": "The same US label of Letairis carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause major birth defects if used by pregnant patients.",
      "context": {
        "id": "cardio:ctx-fda-letairis-label-fetal-risk",
        "label": "The developing fetus, for a person taking ambrisentan during pregnancy, as described in a US label boxed warning",
        "recipient": "fetal",
        "population": "The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Fetus during pregnancy; the passage read gives no gestational ages",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA022081.",
          "snapshot": {
            "id": "cardio:openfda-label-letairis-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:32Z",
            "content_hash": "cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6",
            "source_effective_date": "2026-06-22",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-letairis",
            "source_type": "regulator",
            "title": "openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-letairis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260622.",
          "snapshot": {
            "id": "cardio:openfda-label-letairis-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:32Z",
            "content_hash": "cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6",
            "source_effective_date": "2026-06-22",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-letairis",
            "source_type": "regulator",
            "title": "openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-letairis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0], title",
          "applicability_note": "Label passage quoted in the research quote table (Q-K29-LET-LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-letairis-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:32Z",
            "content_hash": "cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6",
            "source_effective_date": "2026-06-22",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-letairis",
            "source_type": "regulator",
            "title": "openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-letairis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0], first paragraph",
          "applicability_note": "Label passage quoted in the research quote table (Q-K29-LET-LB-07).",
          "snapshot": {
            "id": "cardio:openfda-label-letairis-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:32Z",
            "content_hash": "cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6",
            "source_effective_date": "2026-06-22",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-letairis",
            "source_type": "regulator",
            "title": "openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-letairis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "de7a51c9f6cbfe05c9aabb8ec71210d08d7a0c42dcdfcb285f20bca7c6ffff3f",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-letairis-label-fetal-warning.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-letairis-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:ambrisentan",
      "category": "descriptive",
      "statement": "The US label of Letairis (ambrisentan tablets, Gilead Sciences, Inc., application NDA022081; the version dated 2026-06-22 in openFDA) describes ambrisentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group 1) in adult patients to improve exercise ability and delay clinical worsening.",
      "context": {
        "id": "cardio:ctx-fda-letairis-label-us",
        "label": "Adults with pulmonary arterial hypertension, as described in the US label of Letairis",
        "recipient": "adult",
        "population": "Adult patients with pulmonary arterial hypertension (WHO Group 1), as the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adult patients with pulmonary arterial hypertension (WHO Group 1), as the label states."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists use in combination with tadalafil; that indication is not recorded here. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists a use in combination with tadalafil; that use is not recorded here.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA022081.",
          "snapshot": {
            "id": "cardio:openfda-label-letairis-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:32Z",
            "content_hash": "cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6",
            "source_effective_date": "2026-06-22",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-letairis",
            "source_type": "regulator",
            "title": "openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-letairis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260622.",
          "snapshot": {
            "id": "cardio:openfda-label-letairis-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:32Z",
            "content_hash": "cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6",
            "source_effective_date": "2026-06-22",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-letairis",
            "source_type": "regulator",
            "title": "openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-letairis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K29-LET-LB-04, Q-K29-LET-LB-05).",
          "snapshot": {
            "id": "cardio:openfda-label-letairis-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:32Z",
            "content_hash": "cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6",
            "source_effective_date": "2026-06-22",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-letairis",
            "source_type": "regulator",
            "title": "openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-letairis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "2a945c13c3fc92aff735b318be2d67c47cc8798b95eda1c5c3ba9813ac1bfca1",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-letairis-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Ambrisentan is an endothelin receptor antagonist (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:endothelin-receptor-antagonists",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-358274-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists pulmonary arterial hypertension (WHO Group 1) in adult patients, to improve exercise ability and delay clinical worsening, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-letairis-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "The Letairis label lists use in combination with tadalafil as one indication",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:tadalafil",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/ambrisentan/",
  "context_path": "api/v1/context/cardio--ambrisentan.md"
}
